$CDNA News

CareDx: The Transplant Platform Is Becoming A Specialty Diagnostics Compounder

CareDx Completes Sale Of Its Lab Products Operations To Eurobio Scientific For $171.2M

CareDx (NASDAQ:CDNA) Passes Both the Minervini Trend Template and High Growth Momentum Tests

CareDx, Inc. (CDNA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

CAREDX INC (NASDAQ:CDNA) Shows Perfect Minervini Trend Template and High Growth Momentum Setup

CareDx to Participate in Upcoming Investor Conferences

CareDx Announces Dismissal of 2021 Qui Tam Suit

CareDx's 2021 Qui Tam Action Dismissed; No Monetary Payment Associated With Dismissal

CareDx, Inc. (CDNA) Q1 2026 Earnings Call Transcript

BTIG Maintains Buy on CareDx, Raises Price Target to $28

CareDx (NASDAQ:CDNA) Beats Q1 Estimates and Raises Full-Year Guidance, But Stock Slips

CareDx, Inc. 2026 Q1 - Results - Earnings Call Presentation

CareDx Files For Mixed Shelf; Size Not Disclosed

CareDx Strikes Agreement To Acquire Naveris For $160M Upfront Payment, $100M In Future Milestones

CareDx Raises FY2026 Sales Guidance from $420.000M-$444.000M to $447.000M-$465.000M vs $436.665M Est

CareDx Q1 Adj. EPS $0.34 Beats $0.13 Estimate, Sales $117.700M Beat $104.034M Estimate

CareDx Launches New Test That Matches Organ Donors and Patients in Under 3 Hours, Unveils AlloSeq Nano With 45-Minute Prep and Faster, More Accurate Transplant Matching

CareDx: Watch For Profit-Taking After Recent Positive Preliminary Q1 Results

CareDx Sharpens Focus On Core Testing Services

CareDx shares are trading higher after the company announced it has entered into a definitive agreement to divest its Lab Products business to EuroBio Scientific. The company reported a year-over-year increase in preliminary Q1 revenue results.